The CYTXW chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTXW chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CYTXW stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CYTXW Detailed Price Forecast - CNN Money||View CYTXW Detailed Summary - Google Finance|
|View CYTXW Detailed Summary - Yahoo! Finance||View CYTXW Stock Research & Analysis - Zacks.com|
|View CYTXW Trends & Analysis - Trade-Ideas||View CYTXW Major Holders - Barrons|
|View CYTXW Call Transcripts - NASDAQ||View CYTXW Breaking News & Analysis - Seeking Alpha|
|View CYTXW Annual Report - CompanySpotlight.com||View CYTXW OTC Short Report - OTCShortReport.com|
|View CYTXW Fundamentals - TradeKing||View CYTXW SEC Filings - Bar Chart|
|View Historical Prices for CYTXW - The WSJ||View Performance/Total Return for CYTXW - Morningstar|
|View the Analyst Estimates for CYTXW - MarketWatch||View the Earnings History for CYTXW - CNBC|
|View the CYTXW Earnings - StockMarketWatch||View CYTXW Buy or Sell Recommendations - MacroAxis|
|View the CYTXW Bullish Patterns - American Bulls||View CYTXW Short Pain Metrics - ShortPainBot.com|
|View CYTXW Stock Mentions - StockTwits||View CYTXW Stock Mentions - PennyStockTweets|
|View CYTXW Stock Mentions - Twitter||View CYTXW Investment Forum News - Investor Hub|
|View CYTXW Stock Mentions - Yahoo! Message Board||View CYTXW Stock Mentions - Seeking Alpha|
|View Insider Transactions for CYTXW - SECform4.com||View Insider Transactions for CYTXW - Insider Cow|
|View CYTXW Major Holdings Summary - CNBC||View Insider Disclosure for CYTXW - OTC Markets|
|View Insider Transactions for CYTXW - Yahoo! Finance||View Institutional Holdings for CYTXW - NASDAQ|
|View CYTXW Stock Insight & Charts - FinViz.com||View CYTXW Investment Charts - StockCharts.com|
|View CYTXW Stock Overview & Charts - BarChart||View CYTXW User Generated Charts - Trading View|
Here’s Why Cytori Therapeutics Inc (CYTX) Shares Skyrocketed Today
Posted on Friday January 05, 2018
Cytori Therapeutics Inc (NASDAQ:CYTX) was Wall Street's bull of the day today with shares that flew 74%. The cause of all the enthusiastic commotion? Japanese drug giant Takeda Pharmaceutical intends to acquire TiGenix, an advanced biopharmaceutical company developing novel stem cell therapies for serious medical conditions, at an acquisition price of EUR 1.78 per share, representing a transaction value of approximately EUR 520 million on a fully diluted basis. Investors see the acquisition of Tigenix as a positive "interest" signal for the regenerative medicine space and specifically for Cytori which has a similar adipose based product.
Cytori Therapeutics Inc’s (CYTX) Earnings Declined 36.4%, But How Did It Fare Against The Industry?
Posted on Thursday November 30, 2017
Understanding Cytori Therapeutics Inc’s (NASDAQ:CYTX) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...
Cytori reports 2Q loss
Posted on Thursday August 10, 2017
On a per-share basis, the San Diego-based company said it had a loss of 19 cents. Losses, adjusted for amortization costs, were 18 cents per share. The developer of cell therapies posted revenue of $1.5 ...
Analysts Remain Buyers of 2 Volatile Healthcare Stocks: Cytori Therapeutics Inc (CYTX) and TearLab Corp (TEAR)
Posted on Monday July 24, 2017
Cytori Therapeutics Inc: Should You Catch This Falling Knife? Cytori Therapeutics Inc (NASDAQ:CYTX) shares are crashing over 60% in Monday's trading session, after the biotech company disclosed that its pivotal STAR study assessing Habeo Cell Therapy for the treatment of scleroderma failed to achieve its primary endpoint at week 24 nor any of its secondary endpoints at week 24 or week 48. Kolbert noted, "The totality of the data combined with the investigator comments matter and suggest to us that there maybe a window for approval based on the current data set and/or a small bridging study.